Javascript must be enabled to continue!
CD73-Independent Toxicity of Fludarabine on Adult Normal Bone Marrow Mesenchymal Cells (NBMMC).
View through CrossRef
Abstract
The purine analogue fludarabine is efficient in treating advanced, chronic B-cell lymphocytic leukemia (CLL). We and others have shown that front-line fludarabine treatment impaired the subsequent mobilization of hematopoietic CD34+ cells by G-CSF. This might imply an effect on hematopoietic and/or mesenchymal compartments. We also previously showed that native mesenchymal cells (MC), like expanded MC, express the 5′-ecto-nucleotidase (CD73) which should aid the entry of fludarabine into the cell. So we investigated the toxicity of fludarabine on NBMMC.
We incubated expanded (P1) and fresh NBMMC from femoral heads with increasing doses (0.1 to 6 mMol) of fludarabine for 3 days, and assessed its effect on cell survival (annexin V staining), CFU-F frequency, cell proliferation and immunophenotyping. We used α,β, methylene-adenosine 5 diphosphate (MADP) to inhibit CD73 in order to evaluate its role in the trans-membrane passage of fludarabine.
We observed a direct, dose-dependent toxicity of fludarabine on expanded mesenchymal cells, after 3 days incubation, characterized by apoptosis of 48% of MC. The mesenchymal progenitor cells were more sensitive; their frequency amongst the viable cells, being decreased about 5-fold from the 1mMol dose, to 13-fold at the highest dose, where there were far fewer colonies containing>50 cells. Even after fludarabine removal, viable MC showed an impaired ability to proliferate at the next passage. Fresh NBMMC, incubated under same conditions, showed a similar but lower sensitivity than did expanded (P1) mesenchymal cells, as indicated by a shift in the dose-response curve to a 5-fold decrease at the highest dose. Again, we observed a decreasing proportion of large colonies. MADP provided no significant protection against the effect of fludarabine on fresh or expanded cells. The phenotype of progeny was comparable to that of the controls.
In conclusion, we have shown for the first time that adult NBMMC are sensitive to fludarabine and could prove to be an unexpected in vivo target. The differences between un-manipulated and expanded cells suggest a biologic alteration during culture. The lack of protective effect of MADP and the absence of lower expression of CD73 on resistant cells suggest another route of trans-membrane passage for fludarabine. The consequences of low dose fludarabine incubation on MC properties are currently being studied.
Title: CD73-Independent Toxicity of Fludarabine on Adult Normal Bone Marrow Mesenchymal Cells (NBMMC).
Description:
Abstract
The purine analogue fludarabine is efficient in treating advanced, chronic B-cell lymphocytic leukemia (CLL).
We and others have shown that front-line fludarabine treatment impaired the subsequent mobilization of hematopoietic CD34+ cells by G-CSF.
This might imply an effect on hematopoietic and/or mesenchymal compartments.
We also previously showed that native mesenchymal cells (MC), like expanded MC, express the 5′-ecto-nucleotidase (CD73) which should aid the entry of fludarabine into the cell.
So we investigated the toxicity of fludarabine on NBMMC.
We incubated expanded (P1) and fresh NBMMC from femoral heads with increasing doses (0.
1 to 6 mMol) of fludarabine for 3 days, and assessed its effect on cell survival (annexin V staining), CFU-F frequency, cell proliferation and immunophenotyping.
We used α,β, methylene-adenosine 5 diphosphate (MADP) to inhibit CD73 in order to evaluate its role in the trans-membrane passage of fludarabine.
We observed a direct, dose-dependent toxicity of fludarabine on expanded mesenchymal cells, after 3 days incubation, characterized by apoptosis of 48% of MC.
The mesenchymal progenitor cells were more sensitive; their frequency amongst the viable cells, being decreased about 5-fold from the 1mMol dose, to 13-fold at the highest dose, where there were far fewer colonies containing>50 cells.
Even after fludarabine removal, viable MC showed an impaired ability to proliferate at the next passage.
Fresh NBMMC, incubated under same conditions, showed a similar but lower sensitivity than did expanded (P1) mesenchymal cells, as indicated by a shift in the dose-response curve to a 5-fold decrease at the highest dose.
Again, we observed a decreasing proportion of large colonies.
MADP provided no significant protection against the effect of fludarabine on fresh or expanded cells.
The phenotype of progeny was comparable to that of the controls.
In conclusion, we have shown for the first time that adult NBMMC are sensitive to fludarabine and could prove to be an unexpected in vivo target.
The differences between un-manipulated and expanded cells suggest a biologic alteration during culture.
The lack of protective effect of MADP and the absence of lower expression of CD73 on resistant cells suggest another route of trans-membrane passage for fludarabine.
The consequences of low dose fludarabine incubation on MC properties are currently being studied.
Related Results
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
In Vitro Toxicity of Fludarabine on Normal Bone Marrow (BM) Progenitors Suggests Its Involvement in the Impairment of Hematopoietic Progenitor (HP) Mobilization.
In Vitro Toxicity of Fludarabine on Normal Bone Marrow (BM) Progenitors Suggests Its Involvement in the Impairment of Hematopoietic Progenitor (HP) Mobilization.
Abstract
Fludarabine phosphate (FDR) is considered the most effective drug for treating aggressive B-cell Chronic Lymphocytic Leukemia (B-CLL). Nevertheless, several...
Phenotype of CD39/CD73 expressed on T cells in a mouse model of IPEX syndrome
Phenotype of CD39/CD73 expressed on T cells in a mouse model of IPEX syndrome
Abstract
The combination of CD39 and CD73 degrade ATP to adenosine that shifts ATP-driven pro-inflammatory immune cell activity toward an anti-inflammatory state. Th...
Characterization of Non-Expanded Mesenchymal Progenitors Cells from Normal Adult Human Bone Marrow.
Characterization of Non-Expanded Mesenchymal Progenitors Cells from Normal Adult Human Bone Marrow.
Abstract
Adult Bone Marrow (BM) mesenchymal stem /progenitor cells (MS/PC) are a potentially useful tool for cell therapy and tissue repair. Most of the studies rela...
Abstract 1665: Humanized mice for preclinical efficacy evaluation of drugs targeting CD73
Abstract 1665: Humanized mice for preclinical efficacy evaluation of drugs targeting CD73
Abstract
CD73 expressed in Treg surface facilities the hydrolysis of AMP into adenosine which inhibits the activation, expansion and homing of T effector cells.Thera...
Nucleostemin Gene Expression in Acute Promyelocytic Leukemia Patients.
Nucleostemin Gene Expression in Acute Promyelocytic Leukemia Patients.
Abstract
Abstract 4430
Background
Nucleostemin (NS), a novel p53-binding protein has been shown essential for ste...
Poster 107: The Use of Coacervate Sustained Release System to Identify the Most Potent BMP for Bone Regeneration
Poster 107: The Use of Coacervate Sustained Release System to Identify the Most Potent BMP for Bone Regeneration
Objectives:
Bone morphogenetic proteins (BMPs) belong to the transforming growth factor superfamily that were first discovered by Marshall Urist. There are 14 B...
Myeloma Cell-Derived Runx2 Promotes Myeloma Progression and Bone-Homing
Myeloma Cell-Derived Runx2 Promotes Myeloma Progression and Bone-Homing
Abstract
Background. Multiple myeloma (MM), an incurable plasma-cell malignancy, preferentially grows in bone marrow and frequently metastasizes to new bone sites. T...

